Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Muscle weakness may predict transplant success in blood cancer patients

NCT ID NCT04167683

First seen Dec 17, 2025 · Last updated Jun 21, 2026 · Updated 29 times

Summary

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to understand if muscle health can guide treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Rigshospitalet

    Copenhagen, Denmark

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors predict complications and recovery in stem cell transplant patients by monitoring muscle health.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly improve outcomes. Results may not apply to all patient groups.

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia disease related to hematopoietic stem cell transplant hematologic disorder Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myelodysplastic Syndromes non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.